PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share






Joyce O’Shaughnessy, MD - Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer


Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches, Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.


fyyd: Podcast Search Engine
share








 July 22, 2021  1h39m